Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients

Jiang, Shan; Hill, Kala; Patel, Dipen; Waldeck, A. Reginald; Botteman, Marc; Aly, Abdalla; Norden, Andrew D.

doi:10.1080/13696998.2017.1364258

Cited by 13 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Next, healthcare payments in each phase of care for these patients were studied. Unlike previous studies that used calendar months after diagnosis (7,10,11,13,14), total costs were divided into three clinically relevant phases, i.e., initiation, maintenance and recurrence care. The leading cost was incurred in the initial treatment period ($66,673.80).…”

Section: Resultsmentioning

confidence: 99%

“…However, the majority of these studies were performed a decade ago. Two recent cost studies on HGGs, although with large number of patients from two commercially insured populations, didn't have detailed stage information and they used proxy criteria to identify GBM patients (presumed GBM), and many of their patients might have had low-grade histology (10,11). Additionally, these studies, like many previous reports, did not have patient survival and performance (KPS) information.…”

Section: Discussionmentioning

confidence: 99%

“…Total monthly costs for glioma patients can be 20 times more than for healthy controls (6,9). Previous studies to estimate the cost of glioma care have been based on commercial claims databases, however, such databases suffer several limitations including lack of detailed and verified clinical information (6,10,11). Ray et al, estimated that healthcare costs for these patients were $106,896 in the 6 months postindex surgery and $131,815 in the 12 months postindex surgery (10).…”

mentioning

confidence: 99%

“…Ray et al, estimated that healthcare costs for these patients were $106,896 in the 6 months postindex surgery and $131,815 in the 12 months postindex surgery (10). Similarly, Jiang et al reported that total medical costs for 6 months and 12 months post GBM diagnosis were $160,974 and $201,749, respectively (11). Both of these studies suffer from the advantage and disadvantage of using a large commercial database.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Healthcare Costs for High-grade Glioma

Liu

Tyler²,

Lustick³

et al. 2019

Anticancer Res

View full text Add to dashboard Cite

Background/Αim: Data on verified healthcare costs for high-grade gliomas (HGGs) are limited. This study aimed to determine the healthcare costs for HGGs. Materials and Methods: A total of 88 primary HGGs patients diagnosed and treated at our Institution between 2011 and 2017 who had insurance plans administered with Excellus BCBS were retrospectively identified. Patient clinical information was linked with all verified insurance payment data. Results: Median insurance payments for clinical management of HGGs were $184,159.83. The leading cost was therapeutic radiation oncology. Patients under commercial insurance had a longer survival time, and higher healthcare expenditures in total and in each phase of clinical care. Healthcare costs were higher during therapy initiation and at disease recurrence and lower during the interim. A generalized linear model showed that patients with commercial insurance, better Karnofsky Performance Status, and longer survival time had higher healthcare expenditures. Conclusion: Healthcare payments for HGGs patients were substantial and such high healthcare expenditures were positively associated with patient survival and commercial insurance.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Healthcare Costs for High-grade Glioma

Liu

Tyler²,

Lustick³

et al. 2019

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Estos pacientes presentan altas tasas de morbimortalidad representando altos costos hospitalarios. En un estudio en pacientes asegurados en Estados Unidos tratados por gliomas de alto grado, se observó que representan uno de los grupos de pacientes con mayores costos hospitalarios con incrementos hasta de $180 000 por paciente [9].…”

Section: Introductionunclassified

Relación Entre El Coeficiente De Difusión Aparente y la celularidad. [Relación Entre El Coeficiente De Difusión Aparente yLa Celularidad De Gliomas en Centro de tercer nivel de Panamá]

et al. 2020

View full text Add to dashboard Cite

Resumen Introducción: Los gliomas son tumores malignos altamente celulares del sistema nervioso central. Su grado histológico preoperatorio es de utilidad en el manejo quirúrgico, por lo que la resonancia magnética con secuencias avanzadas intenta brindar mayor información tumoral. Objetivo: Relacionar el coeficiente aparente de difusión (CAD) y celularidad de los gliomas de pacientes entre enero 2015 a diciembre 2017. Metodología:Retrospectivamente se obtuvieron de archivos clínicos la edad, sexo, tipo, grado histológicoy sitio anatómico. Se calculó el CAD en 5mm2 en los estudios de resonancia magnética preoperatorias y se utilizó las laminillas para conteo de celularidad en 5mm2 digitalmente. Se utilizó análisis estadísticos descriptivos y coeficiente de correlación entre CDA con celularidad. Se utilizaron valores de p < 0.05 para significancia estadística. Resultados: 46 casos fueron incluidos, 56.5% fueron hombres. El rango de 41-64 años fueron los más afectados. El glioblastoma fue el tipo histológico más frecuente (47.8%), así como los gliomas de alto grado (73.9%). El 95.7% fueron supratentoriales. La celularidad promedio fue de 3970 ± 2900 vs 2436 ± 948 núcleos/5mm2 (p = 0.13), con valores promedio de CDA mínimo de 0.813 x 10-3 ± 0.229 mm2/s vs 1.052 x 10-3 ± 0.196 mm2/s (p = 0.002), para los gliomas de alto y bajo grado respectivamente. La correlación entre CDA y celularidad fue débil (R = - 0.13, p = 0.37). Conclusión: Existe correlación débil inversamente proporcional entre el CDA y la celularidad con distinción de gliomas de bajo y alto grado con valores de CDA mínimos. Abstract Introduction: Gliomas are highly cellular malignant tumors of the central nervous system. Itspreoperative histological grade is useful in surgical management,so magnetic resonance imaging with advanced sequences tries to provide more tumor information. Objective:Correlateapparent diffusion coefficient (ADC) and cellularity of gliomas of patients between January 2015 to December 2017. Methodology:Data of age, sex, type, histologic grade and anatomic site were retrospectively obtained from clinical archives.The preoperative magnetic resonance ADC was calculated in a 5 mm2 region of interest and the microscope slides were used for the cellularity digitally count in 5 mm2. Descriptive statistical analysis and correlation coefficient between ADC and cellularity were used. Values of p <0.05 were used for statistical significance. Results: 46 cases were included, 56.5% were men. The 41-64 years ranges were the most affected. Glioblastoma was the most frequent histological type (47.8%), as well as high grade gliomas (73.9%). 95.7% were supratentorial. The average cellularity was 3970 ± 2900 vs 2436 ± 948 nuclei/ 5mm2 (p = 0.13), with average minimum ADC values of 0.813 x 10-3 ± 0.229 mm2/s vs 1052 x 10-3 ± 0.196 mm2/s (p = 0.002), for high- and low-grade gliomas, respectively. The correlation between ADC and cellularity was weak (R = - 0.13, p = 0.37). Conclusions:There is a weak inversely proportional correlation between ADC and cellularity. With distinction of low- and high-grade gliomas with minimum ADC values.

show abstract

Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis

Hanna

Lawrie²,

Rogozińska³

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundA glioblastoma is a fatal type of brain tumour for which the standard of care is maximum surgical resection followed by chemoradiotherapy, when possible. Age is an important consideration in this disease, as older age is associated with shorter survival and a higher risk of treatment-related toxicity. ObjectivesTo determine the most e ective and best-tolerated approaches for the treatment of elderly people with newly diagnosed glioblastoma. To summarise current evidence for the incremental resource use, utilities, costs and cost-e ectiveness associated with these approaches. Search methodsWe searched electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase to 3 April 2019, and the NHS Economic Evaluation Database (EED) up to database closure. We handsearched clinical trial registries and selected neuro-oncology society conference proceedings from the past five years. Selection criteriaRandomised trials (RCTs) of treatments for glioblastoma in elderly people. We defined 'elderly' as 70+ years but included studies defining 'elderly' as over 65+ years if so reported. Data collection and analysisWe used standard Cochrane methods for study selection and data extraction. Where su icient data were available, treatment options were compared in a network meta-analysis (NMA) using Stata so ware (version 15.1). For outcomes with insu icient data for NMA, pairwise meta-analysis were conducted in RevMan. The GRADE approach was used to grade the evidence.Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)

show abstract

Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients

Abstract: The direct medical costs of newly-diagnosed, TMZ-treated GBM in commercially insured patients are substantial, with estimated total cumulative costs of $268,031.

Cited by 13 publications

References 17 publications

Healthcare Costs for High-grade Glioma

Healthcare Costs for High-grade Glioma

Relación Entre El Coeficiente De Difusión Aparente y la celularidad. [Relación Entre El Coeficiente De Difusión Aparente yLa Celularidad De Gliomas en Centro de tercer nivel de Panamá]

Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis

Contact Info

Product

Resources

About